Dembrexine

Symptoms such as thick sputum and difficulty in expectoration caused by chronic respiratory diseases have long-term impacts on patients' quality of life and disease recovery progress. Ambroxol bromhexine belongs to the mucolytic expectorant class. It acts on the secretory cells of bronchial glands to regulate the mucus composition of sputum, reduce sputum viscosity, and at the same time enhance the ciliary movement ability of the respiratory mucosa to promote sputum discharge. Clinically, it is mainly used for patients with symptoms of thick sputum that is difficult to expectorate accompanying diseases such as chronic bronchitis, bronchiectasis, and asthma. It can effectively reduce the risk of airway obstruction and the probability of secondary infection.

At present, there is no publicly verifiable statistical data on the global market size of ambroxol bromhexine. In the domestic respiratory expectorant market, this variety is a细分 category with clear clinical application scenarios but a relatively small market share, and the market demand is mainly concentrated in primary medical institutions and respiratory specialty medication scenarios. In terms of the competitive landscape, there are no large-scale generic drugs on the market in China, and the market supply is dominated by imported reagent-grade products, which have not yet been included in the national centralized drug procurement catalogue.

There is no publicly verifiable authoritative registration data on the information related to the original research of ambroxol bromhexine. At present, there are no approved ambroxol bromhexine preparation products on the market in China, and no valid CDE registration number or DMF filing information for the API has been queried. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the R&D and quality control needs of ambroxol bromhexine, CATO can provide a full set of impurity reference standards for this API. Most products are in stock, and orders for in-stock products placed before 16:00 will be shipped on the same day. The products fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and fully meet the use needs of impurity reference standards in the process of drug R&D, quality standard establishment and batch production.